Natera holds a near-monopoly in the minimal residual disease (MRD) testing market. The Austin-based company's flagship product, Signatera, detects cancer recurrence in survivors. Natera’s stock price has roughly quadrupled over the last three years.
The FDA approved Signatera as a companion diagnostic for bladder cancer immunotherapy on May 15, 2026. This marks the first FDA approval for a personalized MRD test used to guide treatment decisions. The approval potentially establishes a new standard of care for cancer survivors.
Analysts value the domestic MRD testing market at approximately $20 billion. Current market penetration sits at only 6%, indicating significant growth potential. Natera reports substantial revenue growth but has not yet achieved profitability.